Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Licenses Genomic Engineering Technology to Novartis

NEW YORK (GenomeWeb News) – Cellectis today announced the licensing of certain patents to Novartis covering certain uses of homologous recombination.

The deal grants the Swiss-based pharmaceutical firm patents for the family WO 90/11354. The technology belongs to the Pasteur Institute and Cellectis owns exclusive rights to them.

The technology allows researchers to introduce new characteristics into genomes.

Financial terms of the deal were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.